|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
During DDP treatment, nude mice in TRIAP1 siRNA group had slower growth and smaller size of transplanted tumor than those in control siRNA group, with increased expression of Cyt c, Apaf-1, and caspase-9.
|
31661694 |
2019 |
|
Malignant neoplasm of breast
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
This study aimed to explore the influence of miR-937 on breast cancer regulation of APAF1 expression.
|
31410016 |
2019 |
|
Breast Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
This study aimed to explore the influence of miR-937 on breast cancer regulation of APAF1 expression.
|
31410016 |
2019 |
|
Seizures
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Western blotting was used to further analyse the expression of Apaf-1, caspase-9, caspase-3, Bcl-2, Bid, Bax, cleaved caspase-3 and cytochrome c. The results showed that compared to the those of the PTZ group, FA pre-treatment significantly (p < 0.01) reduced the Racine scores starting at day 4, prolonged the latency of the onset of seizure at day 28, reduced the escape latency period starting at day 2, increased the frequency of crossing the platform location, increased the SOD activity, reduced the MDA content and apoptosis percentage, and upregulated the Bcl-2 levels whilst downregulating the Bax, cytochrome c, Apaf-1, caspase-9, caspase-3, cleaved caspase-3 and Bid expression levels.
|
31404716 |
2019 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition to apoptosis, Apaf-1 plays critical roles in the intra-S-phase checkpoint; therefore, impaired expression of Apaf-1 has been demonstrated in chemotherapy-resistant malignant melanoma and nuclear translocation of Apaf-1 has represented a favorable prognosis of patients with non-small cell lung cancer.
|
31329620 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
In addition to apoptosis, Apaf-1 plays critical roles in the intra-S-phase checkpoint; therefore, impaired expression of Apaf-1 has been demonstrated in chemotherapy-resistant malignant melanoma and nuclear translocation of Apaf-1 has represented a favorable prognosis of patients with non-small cell lung cancer.
|
31329620 |
2019 |
|
Huntington Disease
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In contrast, increased levels of Apaf-1 protein are observed in the brain in Huntington's disease.
|
31329620 |
2019 |
|
Malignant neoplasm of larynx
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, MEG3 may act as a ceRNA to regulate APAF-1 expression by competitive binding to miR-23a, thereby regulating the progression of laryngeal cancer.
|
31328388 |
2019 |
|
Carcinoma of larynx
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, MEG3 may act as a ceRNA to regulate APAF-1 expression by competitive binding to miR-23a, thereby regulating the progression of laryngeal cancer.
|
31328388 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vitro functional experiments showed that APAF1 depletion increased the tumor potency of cells expressing NAB2-STAT6 fusion protein under treatment with staurosporine.
|
31321477 |
2019 |
|
Solitary fibrous tumor
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our study suggests that dysfunction of TP53 and APAF1 leads to impaired apoptotic function, and eventually contributes toward malignant SFT transformation.
|
31321477 |
2019 |
|
Bladder Neoplasm
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Circular RNA Cdr1as sensitizes bladder cancer to cisplatin by upregulating APAF1 expression through miR-1270 inhibition.
|
31131537 |
2019 |
|
Malignant neoplasm of urinary bladder
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Circular RNA Cdr1as sensitizes bladder cancer to cisplatin by upregulating APAF1 expression through miR-1270 inhibition.
|
31131537 |
2019 |
|
Carcinoma of bladder
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Circular RNA Cdr1as sensitizes bladder cancer to cisplatin by upregulating APAF1 expression through miR-1270 inhibition.
|
31131537 |
2019 |
|
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
In summary, the Apaf-1-mediated suppression of HepG2 cell malignancy is achieved by inhibiting the wnt/β-catenin pathway.
|
31094091 |
2019 |
|
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
In summary, the Apaf-1-mediated suppression of HepG2 cell malignancy is achieved by inhibiting the wnt/β-catenin pathway.
|
31094091 |
2019 |
|
Liver carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Apoptotic protease activating factor-1 negatively regulates Wnt signaling in hepatocellular carcinoma.
|
31094091 |
2019 |
|
Chronic Lymphocytic Leukemia
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Signal transduction mechanism studies indicated that exposure to Cu-NPs activated caspases 3, 8, and 9 and BH3 interacting domain death agonist (tBid), reduced B cell leukemia/lymphoma 2 (Bcl-2) expression, and increased the expression of apoptotic peptidase activating factor 1 (Apaf-1), BCL2-associated X, apoptosis regulator (Bax), and cytochrome c. A microarray analysis revealed significant alterations in the expression of 963 genes; of these, 622 were upregulated and 341 were downregulated.
|
30556269 |
2019 |
|
Leukemia, B-Cell
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Signal transduction mechanism studies indicated that exposure to Cu-NPs activated caspases 3, 8, and 9 and BH3 interacting domain death agonist (tBid), reduced B cell leukemia/lymphoma 2 (Bcl-2) expression, and increased the expression of apoptotic peptidase activating factor 1 (Apaf-1), BCL2-associated X, apoptosis regulator (Bax), and cytochrome c. A microarray analysis revealed significant alterations in the expression of 963 genes; of these, 622 were upregulated and 341 were downregulated.
|
30556269 |
2019 |
|
Multiple Myeloma
|
0.040 |
Biomarker
|
disease |
BEFREE |
FADD or APAF1 gene knockdown in MM cells was achieved by lentiviral transfection.
|
30551468 |
2019 |
|
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
In addition, acetylation at K126 inhibits Hsp70-mediated tumor cell invasion and migration, and the binding of Hsp70 to AIF1 and Apaf1 for promoting mitochondrial-mediated apoptosis.
|
30352233 |
2019 |
|
Tumor Cell Invasion
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
APAF1 expression was regulated by miR-186, while APAF1 knockdown significantly promoted cell invasion and inhibited cell apoptosis.
|
30344679 |
2018 |
|
Squamous cell carcinoma of skin
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
An miR-186 binding site was predicted in APAF1 and their expression was negatively correlated in cSCC tissues.
|
30344679 |
2018 |
|
B-Cell Lymphomas
|
0.050 |
AlteredExpression
|
group |
BEFREE |
The OMECs were pretreated with the MAPK inhibitors before their treatment with V100 for 12 h. V100 increased the apoptosis of OMECs (P < .05), while 3 MAPK inhibitors suppressed V100-induced apoptosis P < .05); V100 enhanced the depolarization of △ψm (P < .05), and SB203580 and U0126 alleviated the V100-induced △ψm decrease (P < .05); V100 downregulated B-cell lymphoma-2 (Bcl-2) and poly [Adenosine diphosphate ribose] polymerase 1 (PARP1) mRNA expression (P < .05), meanwhile it upregulated Bcl-2 associated x (Bax), Apaf1, cytochrome C (CytC) and cysteine aspartase (caspase) 3, 8, 9 mRNA expression (P < .05).
|
30251772 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, it was identified that overexpression of miRNA‑3613‑3p causes significant downregulation of several genes exhibiting tumor suppressive potential [encoding apoptotic protease‑activating factor 1 (APAF1), Dicer, DNA fragmentation factor subunit β, von Hippel‑Lindau protein and neurofibromin 1] in BE(2)‑C human neuroblastoma cells.
|
30066861 |
2018 |